Please login to the form below

Not currently logged in
Email:
Password:

EC approves Pegasys

Roche has revealed that the European Commission approved its hepatitis C medicine, Pegasys. The company says the drug could lead to patients being cured in four months
Roche has revealed that the European Commission (EC) approved its hepatitis C medicine, Pegasys. The company says the drug could lead to patients being cured in four months.

It has been developed as a 16-week treatment for the genotype 2 and 3 strains of hepatitis C in patients with low virus levels. The company hopes that the shorter treatment rates will reduce patients' exposure to drug therapies.

Previous to the approval of Pegasys, patients had to undergo 24 weeks of treatment, even if they had low virus levels and rapid response rates to the medicine.

William Burns, CEO of Roche pharmaceuticals division, explained that the company is committed to advancing the use of personalised medicine, which accounts for patients' reaction and medical history.

"This approval for 16 weeks of treatment in genotype 2 and 3 patients with a rapid response demonstrates the value of using diagnostic tools to determine an individual treatment regime and hopefully will encourage more eligible patients to come forward for treatment," he said.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics